These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

376 related items for PubMed ID: 9834111

  • 1. Lymphotactin gene-modified bone marrow dendritic cells act as more potent adjuvants for peptide delivery to induce specific antitumor immunity.
    Cao X, Zhang W, He L, Xie Z, Ma S, Tao Q, Yu Y, Hamada H, Wang J.
    J Immunol; 1998 Dec 01; 161(11):6238-44. PubMed ID: 9834111
    [Abstract] [Full Text] [Related]

  • 2. [Enhanced antitumor effects induced by lymphotactin gene-modified dendritic cells after pulsed with tumor antigen peptide].
    Zhang W, He L, Cao X.
    Zhonghua Yi Xue Za Zhi; 1999 Mar 01; 79(3):170-3. PubMed ID: 11601032
    [Abstract] [Full Text] [Related]

  • 3. Lymphotactin cotransfection enhances the therapeutic efficacy of dendritic cells genetically modified with melanoma antigen gp100.
    Xia DJ, Zhang WP, Zheng S, Wang J, Pan JP, Wang Q, Zhang LH, Hamada H, Cao X.
    Gene Ther; 2002 May 01; 9(9):592-601. PubMed ID: 11973635
    [Abstract] [Full Text] [Related]

  • 4. Enhanced therapeutic efficacy of tumor RNA-pulsed dendritic cells after genetic modification with lymphotactin.
    Zhang W, He L, Yuan Z, Xie Z, Wang J, Hamada H, Cao X.
    Hum Gene Ther; 1999 May 01; 10(7):1151-61. PubMed ID: 10340547
    [Abstract] [Full Text] [Related]

  • 5. Synergistic enhancement of antitumor immunity with adoptively transferred tumor-specific CD4+ and CD8+ T cells and intratumoral lymphotactin transgene expression.
    Huang H, Li F, Gordon JR, Xiang J.
    Cancer Res; 2002 Apr 01; 62(7):2043-51. PubMed ID: 11929823
    [Abstract] [Full Text] [Related]

  • 6. [Treatment of spontaneous metastatic lung cancer with tumor antigen-pulsed, interleukin-18 gene-modified dendritic cells].
    Chen J, Cao X, Xiu Q.
    Zhonghua Yi Xue Za Zhi; 2001 Jul 10; 81(13):779-82. PubMed ID: 11798964
    [Abstract] [Full Text] [Related]

  • 7. Adenovirus-mediated CD40 ligand gene-engineered dendritic cells elicit enhanced CD8(+) cytotoxic T-cell activation and antitumor immunity.
    Liu Y, Zhang X, Zhang W, Chen Z, Chan T, Ali K, Jia Z, Xiang J.
    Cancer Gene Ther; 2002 Feb 10; 9(2):202-8. PubMed ID: 11857039
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. [Anti-metastatic effect of vascular endothelial growth factor receptor 2 extracellular domain gene-modified dendritic cell vaccination in murine model with experimental pulmonary metastasis].
    Pan JP, Weng YS, Wu QQ.
    Zhonghua Zhong Liu Za Zhi; 2006 Sep 10; 28(9):646-9. PubMed ID: 17274366
    [Abstract] [Full Text] [Related]

  • 11. Adenovirus-mediated intratumoral lymphotactin gene transfer potentiates the antibody-targeted superantigen therapy of cancer.
    Wang Q, Yu H, Zhang L, Ju D, Pan J, Xia D, Yao H, Zhang W, Wang J, Cao X.
    J Mol Med (Berl); 2002 Sep 10; 80(9):585-94. PubMed ID: 12226740
    [Abstract] [Full Text] [Related]

  • 12. Retrovirally transduced bone marrow-derived dendritic cells require CD4+ T cell help to elicit protective and therapeutic antitumor immunity.
    De Veerman M, Heirman C, Van Meirvenne S, Devos S, Corthals J, Moser M, Thielemans K.
    J Immunol; 1999 Jan 01; 162(1):144-51. PubMed ID: 9886380
    [Abstract] [Full Text] [Related]

  • 13. Dendritic cells transduced with recombinant adenoviruses induce more efficient anti-tumor immunity than dendritic cells pulsed with peptide.
    Oh ST, Kim CH, Park MY, Won EH, Sohn HJ, Cho HI, Kang WK, Hong YK, Kim TG.
    Vaccine; 2006 Apr 05; 24(15):2860-8. PubMed ID: 16443309
    [Abstract] [Full Text] [Related]

  • 14. Combined CD4+ Th1 effect and lymphotactin transgene expression enhance CD8+ Tc1 tumor localization and therapy.
    Huang H, Bi XG, Yuan JY, Xu SL, Guo XL, Xiang J.
    Gene Ther; 2005 Jun 05; 12(12):999-1010. PubMed ID: 15789061
    [Abstract] [Full Text] [Related]

  • 15. Immunotherapeutic potential of tumor antigen-pulsed and unpulsed dendritic cells generated from murine bone marrow.
    Yang S, Darrow TL, Vervaert CE, Seigler HF.
    Cell Immunol; 1997 Jul 10; 179(1):84-95. PubMed ID: 9259775
    [Abstract] [Full Text] [Related]

  • 16. Induction of antitumor immunity using bone marrow-generated dendritic cells.
    Porgador A, Snyder D, Gilboa E.
    J Immunol; 1996 Apr 15; 156(8):2918-26. PubMed ID: 8609412
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Augmentation of antitumor immune responses after adoptive transfer of bone marrow derived from donors immunized with tumor lysate-pulsed dendritic cells.
    Asavaroengchai W, Kotera Y, Koike N, Pilon-Thomas S, Mulé JJ.
    Biol Blood Marrow Transplant; 2004 Aug 15; 10(8):524-33. PubMed ID: 15282530
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.